NASDAQ : AFMD

Affimed N.V.

$0.1815 USD

$0 (0.0%)

Volume
22.06M
Average Volume
15.65M
Market Capitalization
$2.98M
P/E Ratio
-0.02
Dividend Yield
0.00%
Price Target
$7.50
Year High
$8.95
Year Low
$0.02
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$3.25
Company Overview

NASDAQ

Shawn Leland

Biotechnology

Healthcare

AFMD

76

DE

USD

https://www.affimed.com

49 6221 6743 60

N01045108

0001608390

Liquidity Metrics

0.33

3.25

3.23

1.49

0.00

Sales & Valuation

$8.28M

0.32

0.04

-0.02

-7.63

Profitability

-$7.09

-$105.94M

-1280.22%

-1280.18%

-100.55%

-109.04%

P/E Metrics

-0.02

0.00

0.00

Analyst Price Target & Rating

$7.50

$10.00

$5.00

N/A

0/5

11 Analysts

-97.58%

Financial Health Scores

-25.63

1/9

$15.61M

$39.96M

$22.76M

-$68.61M

Key Metrics (TTM)

-$16.57M

-2.00

0.16

3.25

-100.55%

-137.41%

-4449.72%

-4363.41%

235 days

Company Executives
Name Title
Melvyn Little Founder & Consultant
Mary Beth Sandin Vice President of Marketing & Communications
Andreas Harstrick Chief Medical Officer & Member of Management Board
Shawn Leland Chief Executive Officer
Wolfgang Fischer MD, Chief Operating Officer, Chief Strategy Officer & Member of Management Board
Michael Wolf Head of Finance & Administration
Denise Mueller Chief Business Officer & Member of Management Board
Alexander Fudukidis Head of Investor Relations & Director of Investor Relations
Poll Results

No votes yet today — be the first to share your view!

About Affimed N.V. (NASDAQ:AFMD) Stock

Affimed N.V. operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts on the identification and advancement of innovative cancer immunotherapies across the United States, Germany, and the broader European region. A key asset in their development pipeline is AFM13. This candidate has successfully concluded its Phase II clinical study for peripheral T-cell lymphoma and is currently progressing through Phase IIa trials for CD30-positive lymphoma, alongside a Phase I trial for Hodgkin lymphoma. Beyond AFM13, Affimed is actively developing several other therapeutic candidates. These include AFM24, a distinctive tetravalent, bispecific innate cell engager designed to target both epidermal growth factor receptor (EGFR) and CD16A; it is presently undergoing Phase IIa cl ... inical trials for a range of advanced cancers. Further back in the pipeline are AFM28, an innate cell engager (ICE) in preclinical development for acute myeloid leukemia, and AFM32, another ICE candidate also in preclinical stages, aimed at solid tumors. The company has forged strategic collaboration agreements with prominent institutions such as The University of Texas MD Anderson Cancer Center, Genentech, Inc., and Roivant Sciences Ltd. Moreover, it benefits from a research funding agreement with The Leukemia & Lymphoma Society. Founded in 2000 and headquartered in Heidelberg, Germany, the organization transitioned its name to Affimed N.V. in October 2014, having previously operated as Affimed Therapeutics B.V.

Frequently Asked Questions

What is the current Affimed N.V. (AFMD) stock price?

Affimed N.V.(NASDAQ:AFMD) stock price is $0.1815 in the last trading session. During the trading session, AFMD stock reached the peak price of $8.95 while $0.018 was the lowest point it dropped to. The percentage change in AFMD stock occurred in the recent session was 0.0% while the dollar amount for the price change in AFMD stock was $0.

AFMD's industry and sector of operation?

The NASDAQ listed AFMD is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of AFMD?

Melvyn Little | Founder & Consultant
Mary Beth Sandin | Vice President of Marketing & Communications
Andreas Harstrick | Chief Medical Officer & Member of Management Board
Shawn Leland | Chief Executive Officer
Wolfgang Fischer | MD, Chief Operating Officer, Chief Strategy Officer & Member of Management Board

How many employees does AFMD have?

Number of AFMD employees currently stands at 76. AFMD operates from Technologiepark, Mannheim, None 69120, DE.

Link for AFMD official website?

Official Website of AFMD is: https://www.affimed.com

How do I contact AFMD?

AFMD could be contacted at phone #49 6221 6743 60 and can also be accessed through its website. AFMD operates from Technologiepark, Mannheim, None 69120, DE.

How many shares of AFMD are traded daily?

The average number of AFMD shares traded daily for last 3 months was 15.65M.

What is the market cap of AFMD currently?

The market value of AFMD currently stands at $2.98M with its latest stock price at $0.1815